The Goldman Sachs Group started coverage on shares of Fulcrum Therapeutics (NASDAQ:FULC – Get Rating) in a research report released on Tuesday, MarketBeat reports. The brokerage issued a buy rating and a $11.00 price target on the stock.
Several other brokerages also recently weighed in on FULC. Stifel Nicolaus lowered their price target on shares of Fulcrum Therapeutics from $43.00 to $35.00 in a report on Thursday, October 20th. Morgan Stanley lifted their price target on shares of Fulcrum Therapeutics from $25.00 to $26.00 and gave the company an overweight rating in a report on Monday. Credit Suisse Group lowered their price target on shares of Fulcrum Therapeutics from $22.00 to $19.00 and set an outperform rating on the stock in a report on Wednesday, November 9th. Piper Sandler reduced their price objective on shares of Fulcrum Therapeutics from $42.00 to $18.00 in a research report on Tuesday, November 8th. Finally, HC Wainwright reiterated a buy rating and set a $20.00 price objective on shares of Fulcrum Therapeutics in a research report on Friday, August 12th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of Moderate Buy and an average price target of $22.71.
Fulcrum Therapeutics Price Performance
Shares of NASDAQ:FULC opened at $7.18 on Tuesday. Fulcrum Therapeutics has a 1-year low of $3.21 and a 1-year high of $24.79. The company has a market capitalization of $373.73 million, a P/E ratio of -2.80 and a beta of 1.94. The firm’s 50 day simple moving average is $7.25 and its two-hundred day simple moving average is $6.98.
Institutional Investors Weigh In On Fulcrum Therapeutics
About Fulcrum Therapeutics
Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
- Get a free copy of the StockNews.com research report on Fulcrum Therapeutics (FULC)
- Power Integrations Stock Can Power Your Portfolio
- Don’t Chase Walmart Higher, Wait For Extra Low Prices
- Home Depot Results (and Institutions) Are A Catalyst For Lowe’s?
- Agilent Remains In Buy Range Ahead Of Next Week’s Q4 Report
- Three Penny Stocks Making Big Moves In November
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.